Looking beyond the 'magic bullet' approach to drug discovery

May 3, 2018, Vanderbilt University
Looking beyond the ‘magic bullet’ approach to drug discovery
Credit: Vanderbilt University

It's time to move beyond the traditional "magic bullet" approach for discovering new drugs and start leveraging the full complexity of Mother Nature, according to Vanderbilt Professor of Chemistry Brian Bachmann and Assistant Professor of Cell and Developmental Biology Jonathan Irish.

The researchers have developed a new process that can rapidly and inexpensively identify personalized drugs derived from nature. They describe their new approach and report how it works on acute myeloid leukemia in a paper published Jan. 2, 2018, in the journal Nature Communications titled "Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics."

"The conventional 'magic bullet' approach to drug development is focused on identifying single molecules that kill disease organisms by disrupting single targets in single artificial cell lines. This has had some successes, but it also has a lot of limitations," said Bachmann, whose research focuses on searching for novel drugs produced by bacteria found in caves, and studying how these drugs are synthesized.

"Within the drug discovery community, there is a tendency to look for simple solutions," said Bachmann. "But life is very complex, as are many diseases, and we need to embrace that complexity to solve complex problems in human medicine."

Many diseases, including many cancers, consist of that possess multiple mutations and redundancies that allow them to compensate for a drug hitting a single target. And the artificial cell lines that researchers often use, like the HeLa isolated from Henrietta Lacks in 1951, do not always behave and respond like naturally occurring—or "wild"—cancer cells found in a patient.

"We wanted to develop a technique that was able to simultaneously detect the effects of multiple compounds against multiple targets in multiple wild cancer cells mixed with normal cells, much as tumors occur in the body," said Irish, who studies the changes in that lead to drug resistance.

In doing so, Bachmann and Irish have brought an old idea—searching for drug ingredients that occur abundantly in nature rather than developing them one at a time in a lab—into the 21st century with cutting-edge scientific tools and computational power.

The researchers began with a type of bacteria known for producing molecules that could affect human health. The bacteria produce thousands of these compounds, called secondary metabolites, to defend themselves from attacks or to attack their competitors. However, they are difficult to discover because the bacteria only produce them under very specific conditions, often in low abundance.

Using a pioneering technique developed in Bachmann's lab two years ago, the researchers stimulated the bacteria to produce large quantities of these chemical defenses. The researchers then combined samples of each individual metabolite with a mixture of healthy and biopsied from real diagnosed with .

They then "bar-coded" the contents of each sample with fluorescent dyes and mixed the samples back together. The researchers used those fluorescent bar codes to quickly analyze how these thousands of metabolites affected the patients' biopsied cells, for better or worse, or not at all.

Advanced computational tools such as machine learning were used to process and recognize patterns in the enormous data sets that emerged from these thousands upon thousands of analyses.

"We call this multiplexed activity metabolomics, or MAM, and it is potentially thousands of times less expensive than traditional methods. It also allows us to simultaneously ask many questions about what the compounds are doing to the cells, unlike traditional assays that each ask a single question," Bachmann said. "This is akin to a shotgun approach, casting a broad net across cellular responses, which can also detect the unexpected."

"This multiplexed approach contrasts with a targeted approach in that it performs a multitude of simultaneous tests and then sorts the results," Irish added. "It is left to us as researchers to identify the interesting results, such as metabolites that result specifically in death of one cell type, such as leukemia cells, and not healthy cells."

The net result is that MAM enables researchers to identify which metabolites or mixtures of metabolites target which type of diseased cells while sparing healthy cells, even down to even how well they might work in a particular patient.

Bachmann and Irish believe that by performing the discovery process with multiple patient samples representing the various major genetic types of cancer, molecules emerging from their pipeline could be developed for use in personalized therapeutics that are tailored to individual patients.

The importance of personalized forms of treatment were illustrated by the tests that the researchers performed on biopsy samples of two leukemia patients: a young woman with a treatable form of the cancer and an older adult male with a drug-resistant form of the disease. They determined that the same metabolites were more toxic to cancer cells in the treatable patient than those in the resistant patient. They also discovered metabolites that targeted the cancer cells in the resistant patient while doing relatively little harm to his .

"Our new technology allows discovery using complex human tissues from patients, without having to experiment directly on people. By leapfrogging past artificial cell lines and animal models of disease, we think this will accelerate the discovery and approval of new therapeutics for complex human diseases such as cancer," Bachmann said.

The researchers don't plan to stop with cancer-killers. "In the future, we plan to use the system to look for more complex patterns, such as activating immune cells while suppressing cancer cells or differentiating a particular cell type into a useful type of specialized cell," Irish said. "Since we can look for molecules with positive and negative impacts at the same time, we imagine the MAM system being used for regenerative medicine as well as ."

Explore further: Two drugs are better than one in fight against leukaemia

More information: David C. Earl et al. Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics, Nature Communications (2017). DOI: 10.1038/s41467-017-02470-8

Related Stories

Two drugs are better than one in fight against leukaemia

March 8, 2018
Adelaide scientists have devised a way to enhance the effectiveness of a patient's leukaemia treatment by using a combination of drugs.

Bolstering fat cells offers potential new leukemia treatment

October 16, 2017
Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients, according to a new study from McMaster University.

Researchers discover new approach to stimulate an immune response against tumor cells

January 30, 2018
New drugs that activate the immune system to target cancer cells have improved the lives of many patients with cancer. However, immunotherapies are not effective in all patients, and the success of these therapies depends ...

Study provides first systematic survey of metabolites across tumor types

January 25, 2018
In an advance reminiscent of the earliest maps of genomic mutations in cancer, investigators at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center have completed the first systematic survey of the products ...

Team develops technology to find optimum drug target for cancer

December 18, 2017
A KAIST research team led by Professor Kwang-Hyun Cho of the Department of Bio and Brain Engineering developed technology to find the optimum drug targets for specific types of cancer cells. The team used systems biology ...

Researchers discover new targets for approved cancer drug

October 10, 2017
Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs ...

Recommended for you

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.